Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

FDA approves Regeneron’s hearing loss gene therapy

 April 23, 2026

BioPharma Dive

Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA s national priority voucher program and will be offered to eligible patients at n

RegulatoryGene TherapyRead full story

Post navigation

FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program →
← Cumberland to sell drug portfolio to Apotex for $100m

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com